Aposcience AG scientists have made the seminal observation that a complex mixture of cytokines, growth factors, lipids and exosomes are released from peripheral white blood cells and has beneficial therapeutic effects in multiple preclinical experimental models. Aposec (TM) has proven preclinical efficacy in acute myocardial infarction, stroke, spinal cord injury, myocarditis, and wound healing.

Furthermore, we have shown that Aposec induces multiple modes of actions (MoAs) in vitro and vivo that are causative for the resolution of inflammation after hypoxia induced damage.

GMP production of Aposec for the use in clinical trials has been approved by the regulatory body.

Aposec was developed as a biological according to ICH guidelines.